Kura Oncology’s (KURA) Buy Rating Reiterated at TD Cowen

TD Cowen restated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a report published on Thursday morning,Benzinga reports.

Other research analysts have also recently issued reports about the company. StockNews.com cut Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday. UBS Group initiated coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They issued a “buy” rating and a $27.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research note on Thursday. Stifel Nicolaus downgraded Kura Oncology from a “buy” rating to a “hold” rating and reduced their target price for the stock from $26.00 to $19.00 in a report on Monday, October 14th. Finally, Jefferies Financial Group dropped their price target on Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a report on Thursday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.38.

Kura Oncology Trading Up 7.4 %

Shares of KURA opened at $10.80 on Thursday. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The stock has a market cap of $839.81 million, a PE ratio of -4.58 and a beta of 0.86. Kura Oncology has a 1 year low of $9.06 and a 1 year high of $24.17. The stock has a 50 day simple moving average of $17.88 and a 200-day simple moving average of $19.69.

Institutional Trading of Kura Oncology

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in shares of Kura Oncology in the 1st quarter valued at about $110,000. ProShare Advisors LLC lifted its holdings in Kura Oncology by 9.7% in the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock valued at $384,000 after buying an additional 1,588 shares during the period. Vanguard Group Inc. boosted its stake in Kura Oncology by 0.7% in the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after acquiring an additional 28,212 shares during the last quarter. Avoro Capital Advisors LLC grew its holdings in Kura Oncology by 29.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock worth $82,120,000 after acquiring an additional 870,000 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Kura Oncology by 17.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock valued at $430,000 after acquiring an additional 2,940 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.